Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 3;3(4):100298.
doi: 10.1016/j.jacig.2024.100298. eCollection 2024 Nov.

PANoptosis opens new treatment options for allergic bronchopulmonary aspergillosis

Affiliations

PANoptosis opens new treatment options for allergic bronchopulmonary aspergillosis

Dalan Smallwood et al. J Allergy Clin Immunol Glob. .

Abstract

Background: Allergic bronchopulmonary aspergillosis (ABPA) is a rare airway disorder primarily affecting patients with asthma and cystic fibrosis. Persistent airway inflammation brought on by Aspergillus fumigatus exacerbates the underlying condition and can cause significant respiratory damage. Treatments center on reducing inflammation with the use of corticosteroids and antifungals. PANoptosis is a new concept in the field of cell death and inflammation that posits the existence of cross talk and a master control system for the 3 programmed cell death (PCD) pathways, namely, apoptosis, pyroptosis, and necroptosis. This concept has revolutionized the understanding of PCD and opened new avenues for its exploration. Studies show that Aspergillus is one of the pathogens that is capable of activating PANoptosis via the Z-DNA binding protein 1 (ZBP1) pathway and plays an active role in the inflammation caused by this organism.

Objective: This article explores the nature of inflammation in ABPA and ways in which PCD could lead to novel treatment options.

Method: PubMed was used to review the literature surrounding Aspergillus infection-related inflammation and PANoptosis.

Results: There is evidence that apoptosis and pyroptosis protect against Aspergillus-induced inflammation, whereas necroptosis promotes inflammation.

Conclusion: Experimental medications, in particular, necroptosis inhibitors such as necrosulfonamide and necrostatin-1, should be studied for use in the treatment of ABPA.

Keywords: ABPA; Aspergillus fumigatus; PANoptosis; TAK1; ZBP1; allergic bronchopulmonary aspergillosis; apoptosis; necroptosis; programmed cell death; pyroptosis.

PubMed Disclaimer

Conflict of interest statement

The N. Kolliputi laboratory is funded by the Joy McCann Culverhouse endowment to the Division of Allergy and Immunology. Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

Figures

Fig 1
Fig 1
PANoptosis is suspected to be induced by A fumigatus. Evidence suggests there may be a cyclopentanediol analog produced by A fumigatus that serves as an inhibitor of TAK1. In addition, direct activation can occur through an unknown Z-DNA ligand binding to ZBP1. The PANoptosome complex formed from either pathway can then go on to induce the 3 modalities of cell death, namely, apoptosis, pyroptosis, and necroptosis. ASC, Adapter apoptosis-associated speck-like protein containing a caspase recruitment domain; CASP8, caspase-8; FADD, FAS-associated via death domain.
Fig 2
Fig 2
A fumigatus–induced cell death. Solid lines represent known relationships, dashed lines represent suspected relationships based on studies in C albicans. A fumigatus conidia inhibits apoptosis through the secretion of dihydroxynapthalene-melanin (DHN-melanin). Once it has germinated, A fumigatus has multiple virulence factors capable of inducing the 3 different cell death pathways. Gliotoxin serves as an activator of apoptosis. Ergosterol and chitin are known virulence factors of A fumigatus but have not been directly shown to activate the pyroptosis pathway in aspergillosis. Activation of dectin-1 via β-glucan has been demonstrated to play a role in the pyroptosis pathway but is currently only suspected in necroptosis.

References

    1. Harada T., Inui G., Ishikawa H., Kato R., Sueda Y., Funaki Y., et al. The clinical characteristics of allergic bronchopulmonary mycosis differ among pathogenic fungi. Yonago Acta Med. 2023;66:257–262. - PMC - PubMed
    1. Asano K., Hebisawa A., Ishiguro T., Takayanagi N., Nakamura Y., Suzuki J., et al. New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation. J Allergy Clin Immunol. 2021;147:1261–1268.e5. - PubMed
    1. Denning D.W., Pleuvry A., Cole D.C. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013;51:361–370. - PubMed
    1. Maturu V.N., Agarwal R. Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis. Clin Exp Allergy. 2015;45:1765–1778. - PubMed
    1. Roboubi A., Audousset C., Frealle E., Brun A.L., Laurent F., Vitte J., et al. Allergic bronchopulmonary aspergillosis: a multidisciplinary review. J Mycol Med. 2023;33 - PubMed

LinkOut - more resources